Identification and functional characterization of a new human kidney–specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2
S Masuda, T Terada, A Yonezawa… - Journal of the …, 2006 - journals.lww.com
A cDNA coding a new H+/organic cation antiporter, human kidney-specific multidrug and toxin
extrusion 2 (hMATE2-K), has been isolated from the human kidney. The hMATE2-K cDNA …
extrusion 2 (hMATE2-K), has been isolated from the human kidney. The hMATE2-K cDNA …
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion …
A Yonezawa, S Masuda, S Yokoo, T Katsura… - Journal of Pharmacology …, 2006 - ASPET
We have examined the role of the human organic cation transporters [hOCTs and human
novel organic cation transporter (hOCTN); SLC22A1–5] and apical multidrug and toxin …
novel organic cation transporter (hOCTN); SLC22A1–5] and apical multidrug and toxin …
Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity
S Yokoo, A Yonezawa, S Masuda, A Fukatsu… - Biochemical …, 2007 - Elsevier
The mechanism of severe nephrotoxicity caused by cisplatin, but not carboplatin, oxaliplatin,
and nedaplatin, is not fully understood. The renal accumulation and subsequent …
and nedaplatin, is not fully understood. The renal accumulation and subsequent …
Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons
Y Takada, A Yonezawa, T Kume, H Katsuki… - … of Pharmacology and …, 2003 - ASPET
Donepezil is a potent and selective acetylcholinesterase (AChE) inhibitor developed for the
treatment of Alzheimer's disease. To elucidate whether donepezil shows neuroprotective …
treatment of Alzheimer's disease. To elucidate whether donepezil shows neuroprotective …
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity
T Nakamura, A Yonezawa, S Hashimoto… - Biochemical …, 2010 - Elsevier
Multidrug and toxin extrusion 1 (MATE1/SLC47A1) is expressed in the brush-border membrane
of renal proximal tubules and mediates the efflux of cationic drugs. In the present study, …
of renal proximal tubules and mediates the efflux of cationic drugs. In the present study, …
Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics
A Yonezawa, K Inui - British journal of pharmacology, 2011 - Wiley Online Library
The renal organic cation transport system mediates the tubular secretion of cationic
compounds including drugs, toxins and endogenous metabolites into urine. It consists of a …
compounds including drugs, toxins and endogenous metabolites into urine. It consists of a …
Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat
A Yonezawa, S Masuda, K Nishihara, I Yano… - Biochemical …, 2005 - Elsevier
Cisplatin is an effective anticancer drug, but has its severe adverse effects, especially
nephrotoxicity. The molecular mechanism of cisplatin-induced nephrotoxicity is still not clear. In the …
nephrotoxicity. The molecular mechanism of cisplatin-induced nephrotoxicity is still not clear. In the …
Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents
A Yonezawa, K Inui - Biochemical pharmacology, 2011 - Elsevier
Platinum agents have been widely used in cancer chemotherapy for a long time. Cisplatin,
carboplatin, oxaliplatin and nedaplatin have a common chemical structure consisting of …
carboplatin, oxaliplatin and nedaplatin have a common chemical structure consisting of …
Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2
…, A Al-Odaib, AJ Abrams, K Sugano, A Yonezawa… - Brain, 2014 - academic.oup.com
Childhood onset motor neuron diseases or neuronopathies are a clinically heterogeneous
group of disorders. A particularly severe subgroup first described in 1894, and subsequently …
group of disorders. A particularly severe subgroup first described in 1894, and subsequently …
[HTML][HTML] Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain
Y Yao, A Yonezawa, H Yoshimatsu, S Masuda… - The Journal of …, 2010 - Elsevier
We isolated cDNA coding a new human riboflavin transporter (hRFT)3, which exhibits 86.7
and 44.1% amino acid identity with hRFT1 and hRFT2, respectively. It was predicted to have …
and 44.1% amino acid identity with hRFT1 and hRFT2, respectively. It was predicted to have …